Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 01, 2024
Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 25, 2022
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project.
Journal: Molecular therapy oncolytics
Published: February 24, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Journal: The oncologist
Published: November 05, 2021
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 21, 2021
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 31, 2018
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 28, 2018
Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research.
Journal: Urologic oncology
Published: September 30, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026